EICHOR
● No Longer Available
Expanded Access Program for RP in Adults
Condition: Retinitis Pigmentosa · Sponsor: Ocugen
About this study
This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (5)
| Associated Retina Consultants | Phoenix, Arizona, United States | — |
| Advanced Research | Deerfield Beach, Florida, United States | — |
| Erie Retina Research | Erie, Pennsylvania, United States | — |
| Valley Retina Institute | McAllen, Texas, United States | — |
| Gundersen Health | La Crosse, Wisconsin, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06574997